Wick Capital Partners LLC Acquires 792 Shares of Eli Lilly and Company $LLY

19 Jun 2026, 09:14 by Doug Wharley · The Cerbat Gem

Wick Capital Partners LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 169.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,259 shares of the company’s stock after purchasing an additional 792 shares during the quarter. Wick Capital Partners LLC’s holdings in Eli Lilly and Company were worth $1,353,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $25,000. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth about $30,000. Miller Global Investments LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $33,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares in the last quarter. Finally, Dorato Capital Management acquired a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $36,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,098.78 on Friday. The stock has a 50 day moving average price of $1,013.17 and a 200 day moving average price of $1,016.84. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market capitalization of $1.03 trillion, a PE ratio of 39.03, a price-to-earnings-growth ratio of 1.22 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same period last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a $1.73 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Several articles highlighted Eli Lilly’s strong growth profile and ongoing investor support, including coverage that Ray Dalio’s Bridgewater sees LLY as a top growth name and that some analysts view the stock as undervalued on its growth narrative. Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio
Positive Sentiment: Lilly’s pipeline news was broadly constructive, including completion of a retatrutide trial and early signs from its AJX-101 study, which suggest continued momentum in diabetes, obesity, and immunology programs. Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio
Positive Sentiment: The company also expanded its AI drug-discovery ecosystem, with Charles River, Chai Discovery, and Axcelead DDP joining Lilly TuneLab, supporting longer-term innovation and partnership potential. Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
Neutral Sentiment: Recent articles also noted Lilly remains a major leader in obesity treatment, with investor debate around whether newer competitors like Pfizer can take share; this underscores the size of the opportunity but also the competitive backdrop. Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
Negative Sentiment: One of the bigger drags on sentiment was Lilly’s decision to halve a planned €2.7 billion Germany investment, citing European drug-pricing reforms that could pressure future R&D and manufacturing commitments. Eli Lilly (LLY) Halves $2.7 Billion Germany Investment Over Europe Drug Pricing
Negative Sentiment: Another potential overhang is Lilly beginning to deny some 340B discounts, which could increase policy and pricing friction with healthcare providers and public programs. Eli Lilly begins denying 340B discounts

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on LLY shares. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

Get Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).